AllianceBernstein
MAZE

AllianceBernstein’s Maze Therapeutics MAZE Stock Holding History

AllianceBernstein’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
37,800
-26,962
-42% -$707K ﹤0.01% 2331
2026
Q1 		$2.68M Buy
64,762
+31,542
+95% +$1.39M ﹤0.01% 1837
2025
Q4 		$1.38M Sell
33,220
-26,880
-45% -$924K ﹤0.01% 2202
2025
Q3 		$1.56M Buy
60,100
+28,304
+89% +$478K ﹤0.01% 2142
2025
Q2 		$390K Sell
31,796
-984,650
-97% -$10.2M ﹤0.01% 2786
2025
Q1 		$11.2M Buy
+1,016,446
New +$12.2M ﹤0.01% 1115

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

AllianceBernstein's MAZE Position: Q2 2026 in Review

AllianceBernstein reduced its Maze Therapeutics (MAZE) stake by 42% in Q2 2026, selling an estimated $707K and leaving 37,800 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

AllianceBernstein first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $11.2M in Q1 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • AllianceBernstein held 37,800 shares of Maze Therapeutics worth $1.13M as of Q2 2026.
  • AllianceBernstein sold 26,962 Maze Therapeutics shares in Q2 2026, an estimated $707K.
  • Maze Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2331 holding.
  • AllianceBernstein first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • AllianceBernstein's Maze Therapeutics position peaked at $11.2M in Q1 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.